Loading
Polyomavirus and Related Diseases · Journal article
The Journal of Dermatology · September 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This case series describes three patients with advanced, treatment-refractory merkel cell carcinoma treated with lutetium-177 oxodotreotide after ICI and chemotherapy failure. All three progressed, with survival from first PRRT ranging from 1.4 to 4.2 months; one achieved transient disease stabilization. No serious adverse events were reported, but the limited antitumor efficacy and small sample preclude any conclusions about clinical benefit.
Case series. Three patients with advanced MCC (aged 73, 45, and 77 years) who had failed or were intolerant of immune checkpoint inhibitor therapy and cytotoxic chemotherapy. All demonstrated SSTR uptake on 111In pentetreotide imaging, establishing treatment eligibility.. Intervention: 177Lu-oxodotreotide (peptide receptor radionuclide therapy). n = 3.
Three patients aged 73, 45, and 77 years with advanced MCC treated with 177Lu-oxodotreotide after ICI and chemotherapy failure All three patients experienced disease progression; one achieved transient disease stabilization with tumor reduction Survival from first PRRT administration: 3.4, 4.2, and 1.4 months respectively
No serious treatment-related adverse events observed
Lutetium-177 oxodotreotide may be a feasible and safe salvage option for MCC patients with ICI/chemotherapy failure, but limited antitumor efficacy in this small series does not support its routine adoption. Prospective studies are needed to establish clinical role.
Three uncontrolled case reports of a salvage therapy in treatment-refractory merkel cell carcinoma, showing feasibility and safety but limited efficacy; early evidence requiring prospective study.
As stated by the source record.
Quoted from the source exactly as published.
Lutetium-177 oxodotreotide may be a feasible and safe salvage option for MCC patients with ICI/chemotherapy failure, but limited antitumor efficacy in this small series does not support its routine adoption. Prospective studies are needed to establish clinical role.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer associated with early metastasis and poor outcomes in the advanced stages. Immune checkpoint inhibitors (ICIs), particularly avelumab, represent the first‐line therapy for metastatic MCC. However, effective treatment options after progression or intolerance remain limited. Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has emerged as a potential therapeutic option for tumors expressing somatostatin receptors (SSTRs). We present three patients with advanced MCC (aged 73, 45, and 77 years, respectively) treated with 177 Lu‐oxodotreotide after failure or intolerance of ICI therapy and cytotoxic chemotherapy. 111 In pentetreotide single photon emission computed tomography/computed tomography demonstrated SSTR uptake in all patients, supporting the rationale for PRRT. All patients ultimately experienced disease progression; however, one achieved transient disease stabilization with tumor reduction. The times from the first PRRT administration to death were 3.4, 4.2, and 1.4 months, respectively. No serious treatment‐related adverse events were observed. These findings suggest that 177 Lu‐oxodotreotide may represent a feasible and relatively safe option for patients with treatment‐refractory MCC, although its antitumor efficacy is limited. However, further prospective studies are required to elucidate its clinical role.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.